GoKawiilResearchers develop drugs that mimic exercise's effects in mice and early human trials
Pharmacologist Thomas Burris and colleagues created a compound that activates a muscle receptor normally boosted by exercise, producing mice with greater endurance and possible cognitive and heart-failure benefits; Burris founded Pelagos to pursue a clinical trial. Separately, biotech firm Cambrian Bio reported in June that its drug ATX-304 raised metabolism and cut liver and belly fat in obese, prediabetic patients by activating an energy-sensing cellular switch.
GoKawiil's interpretation of the reporting above, not reported fact.
These efforts suggest science is moving toward drugs that replicate specific physiological effects of exercise rather than exercise itself, which could benefit people unable to work out due to illness or disability. However, Burris notes the FDA approves treatments for disease, not wellness enhancement, meaning such drugs may face a steep regulatory path unless tied to specific conditions like obesity or diabetes.
- Burris's compound made 'marathon mice' by activating a receptor linked to endurance, with possible cognitive and cardiac benefits.
- Cambrian Bio's ATX-304 improved metabolism and reduced fat in human obesity/prediabetes patients, potentially preserving muscle unlike GLP-1 drugs.
- Regulatory approval remains uncertain since the FDA targets disease treatment, not general fitness enhancement.
Source: technologyreview.com — Cassandra Willyard, 2026-10-21
Published there as: “Exercise in a pill”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.